Physician profile
Yahima Balboa
NPI 1972029809
$8,470.10
in general payments reported to CMS, 2019-2025
50 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,665 · 2022: $1,419 · 2023: $1,573 · 2024: $2,497 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,759 · Travel and Lodging: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.07 |
| Travel and Lodging | $627.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,612.58 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $1,199.86 | 2022-2024 | Minimed 780g, Minimed 770g, Mycarelink |
| Biohaven Pharmaceuticals, INC. | $1,013.10 | 2021 | |
| Lilly USA, LLC | $580.12 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $386.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $378.26 | 2021-2024 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $317.64 | 2022-2024 | |
| Tandem Diabetes Care, INC. | $250.20 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $236.54 | 2023-2025 | Omnipod |
| Amarin Pharma, INC. | $234.32 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $210.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $163.91 | 2021-2024 | |
| Glaxosmithkline, LLC. | $127.83 | 2021-2023 | Shingrix, Arexvy |
| Regeneron Healthcare Solutions, INC. | $121.81 | 2024 | Libtayo |
| Abbott Laboratories | $116.93 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yahima Balboa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.